I

Iovance Biotherapeutics

TIL-based T-cell therapies for solid tumors

Commercial Lead

Field SalesConfirmed live in the last 24 hours
Full-timeNo salary listed

About the Job

Requirements

  • A relevant bachelor's degree or an equivalent combination of education and senior commercial leadership experience is required.
  • Extensive progressive experience in oncology or biotechnology commercial and customer-facing leadership roles, typically gained through 12 or more years of relevant experience.
  • Demonstrated success leading a pharmaceutical or biotechnology product launch at the country or regional level.
  • Demonstrated profit-and-loss ownership and delivery against revenue, operating expense, budget and profitability targets.
  • Experience leading an end-to-end sales process tied to patient treatment, administration or infusion, including demand generation, patient conversion, completed treatment and revenue recognition.
  • Strong forecasting, financial planning, budget management, business analytics and performance-management experience.
  • Experience building a market, commercial capability or country organisation with limited existing infrastructure.
  • Experience in, or demonstrated ability to learn, the cellular therapy field, including service-line operations, quality, cell laboratories and nursing.
  • A strong understanding of the environment and influences affecting treatment-centre providers and personnel.
  • High clinical aptitude in oncology and immunotherapy, with strong operational and commercial acumen in tertiary hospital and community oncology settings.
  • Executive presence and demonstrated ability to influence senior internal and external stakeholders and deliver compelling oral presentations.
  • Ability to manage competing priorities, make sound decisions and meet time-sensitive business requirements.
  • Ability to lead effectively through influence within a matrix organisation and build organisational capability as the Australian business grows.
  • The successful candidate must be based in Australia and have ongoing legal working rights in Australia.
  • A current driver license and the ability to undertake regular domestic travel, anticipated to be up to 75%, are inherent requirements of the role.
  • The role requires regular use of standard office technology and participation in virtual and in-person meetings.

Responsibilities

  • Own and lead the Australian commercialisation strategy, launch plan and ongoing business performance for AMTAGVI and Proleukin.
  • Hold profit-and-loss accountability for the Australian business, including revenue, operating expenses, forecasts, budgets, investments, resource allocation and profitability.
  • Establish annual and long-range commercial plans, performance measures and resource priorities aligned with global business objectives.
  • Lead the full sales cycle across authorised treatment centres and referral networks, from opportunity identification, account planning and customer education through patient identification, referral, treatment scheduling, completed infusion, revenue generation and ongoing account growth.
  • Achieve patient infusion, demand and revenue targets for AMTAGVI and Proleukin while maintaining compliance with applicable laws, regulations and company policies.
  • Build and manage the Australian commercial forecast using treatment-centre readiness, referral activity, patient identification, scheduling, manufacturing, infusion and revenue data.
  • Develop and maintain executive, clinical and operational relationships with treatment centres, referral sites, health-service leaders, clinicians, Commonwealth and state health authorities, public and private funders, reimbursement stakeholders, hospital decision-makers and other partners required to establish and expand TIL therapy in Australia.
  • Lead the TIL treatment-centre authorisation process using risk-based tools for authorisation, training, monitoring and disqualification, and provide ongoing operational and quality oversight of authorised treatment centres.
  • Lead operational meetings with medical leadership from medical oncology, surgery and cell therapy to establish a standard-of-care pathway for TIL therapy.
  • Lead cross-functional treatment-centre meetings with nursing, laboratory, pharmacy, quality and operational champions to develop product and patient workflows and remove barriers to treatment.
  • Develop and execute training for authorised users and ensure access to chain-of-identity and chain-of-custody systems is provided to trained individuals.
  • Lead cross-functional execution across Market Access, Treatment Centre Operations, Medical Affairs, Business Analytics, Finance, Human Resources, Legal, Supply Chain, Patient Services and global commercial teams.
  • Serve as the senior business representative for Australia in global planning, forecasting, investment and performance reviews.
  • Design the future Australian commercial organisation and lead the selection, development and performance of additional team members as the market grows.
  • Lead or participate in advisory board meetings to identify market-development and educational needs.
  • Adhere to Iovance Biotherapeutics' core values and business ethics.
  • Maintain compliance with corporate policies and procedures and with Australian healthcare laws and regulations.
  • Perform other duties reasonably within the scope of the role, as required.

Desired Qualifications

  • An MBA or other relevant postgraduate qualification is preferred.
  • Cell therapy and hospital experience are strongly preferred.
  • Solid tumour launch experience is preferred.
  • Experience developing and building service lines at public or private teaching hospitals or tertiary hospitals is preferred, with a strong understanding of transplant or cell therapy service lines.

About the Company

Iovance Biotherapeutics

TIL-based T-cell therapies for solid tumors

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company size
501-1,000
Company stage
IPO
Headquarters
San Carlos, CA
Founded
2007

Recently Posted Jobs

Explore more opportunities at Iovance Biotherapeutics

See more jobs